A Phase 1 interventional study of Lebrikizumab and Placebo in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-12.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purpose of this study is to determine the tolerability and side effects related to lebrikizumab comparing with placebo given as a single dose administered under the skin to healthy Chinese participants. The study will also assess how fast lebrikizumab gets into the blood stream and how long the body takes to get rid of it. Each enrolled participant will receive a single dose of either Lebrikizumab or placebo.
For each participant, the total duration of the study will be approximately up to 21 weeks, including screening period.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received single dose of 250 milligram (mg) lebrikizumab administered as subcutaneous (SC) injection on day 1.
Drug: Lebrikizumab
Participants received single dose of 500 mg lebrikizumab administered as SC injection on day 1.
Drug: Lebrikizumab
Participants received single dose of placebo administered as SC injection on day 1.
Drug: Placebo
Administered subcutaneously (SC)
Also known as: LY3650150
Administered subcutaneously (SC)
Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs)
A TEAE is defined as an AE that starts during or after dosing, or starts prior to dosing and increases in severity after dosing. A SAE is defined as any untoward medical occurrence that, at any dose, meets one or more of the criteria listed: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; is a congenital anomaly/birth defect; is an important medical event that may require medical or surgical intervention to prevent any of the above outcomes. A summary of TEAEs, SAEs and other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events section of this record.
Time frame: Baseline up to 120 days
Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Lebrikizumab
PK: Cmax of Lebrikizumab is reported.
Time frame: Day 1: Predose and Days 2, 5, 8, 11, 15, 22, 29, 43, 57, 71, 85, and 120 post dose
PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC [0-∞]) of Lebrikizumab
PK: AUC0-∞ of Lebrikizumab is reported.
Time frame: Day 1: Predose and Days 2, 5, 8, 11, 15, 22, 29, 43, 57, 71, 85, and 120 post dose
PK: Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC[0-tlast]) of Lebrikizumab
PK: AUC0-tlast of Lebrikizumab is reported.
Time frame: Day 1: Predose and Days 2, 5, 8, 11, 15, 22, 29, 43, 57, 71, 85, and 120 post dose
| Milestone | 250 mg Lebrikizumab | 500 mg Lebrikizumab | Placebo |
|---|---|---|---|
| Started | 10 | 10 | 4 |
| Received at least one dose of study drug | 10 | 10 | 4 |
| Completed | 10 | 10 | 4 |
| Not completed | 0 | 0 | 0 |
A TEAE is defined as an AE that starts during or after dosing, or starts prior to dosing and increases in severity after dosing. A SAE is defined as any untoward medical occurrence that, at any dose, meets one or more of the criteria listed: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; is a congenital anomaly/birth defect; is an important medical event that may require medical or surgical intervention to prevent any of the above outcomes. A summary of TEAEs, SAEs and other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events section of this record.
| participants | 250 mg Lebrikizumab | 500 mg Lebrikizumab | Placebo |
|---|---|---|---|
| TEAEs | 10 | 10 | 3 |
| SAEs | 0 | 0 | 0 |
PK: Cmax of Lebrikizumab is reported.
| microgram per millilitre (µg/mL) | 250 mg Lebrikizumab | 500 mg Lebrikizumab |
|---|---|---|
| Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Lebrikizumab | 26.8 ± 41.9 | 71.2 ± 22.1 |
PK: AUC0-∞ of Lebrikizumab is reported.
| microgram*day per milliliter (μg*day/mL) | 250 mg Lebrikizumab | 500 mg Lebrikizumab |
|---|---|---|
| PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC [0-∞]) of Lebrikizumab | 1130 ± 42.2 | 2940 ± 11.2 |
PK: AUC0-tlast of Lebrikizumab is reported.
| μg*day/mL | 250 mg Lebrikizumab | 500 mg Lebrikizumab |
|---|---|---|
| PK: Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC[0-tlast]) of Lebrikizumab | 1080 ± 40.8 | 2800 ± 11.7 |
Collected over Baseline Up to 120 Days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 250 mg Lebrikizumab | 0/10 (0%) | 0/10 (0%) | 10/10 (100%) |
| 500 mg Lebrikizumab | 0/10 (0%) | 0/10 (0%) | 10/10 (100%) |
| Placebo | 0/4 (0%) | 0/4 (0%) | 3/4 (75%) |
| Event | 250 mg Lebrikizumab | 500 mg Lebrikizumab | Placebo |
|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 4/10 | 2/10 | 0/4 |
| Mouth ulcerationGastrointestinal disorders | 3/10 | 1/10 | 1/4 |
| Bilirubin conjugated increasedInvestigations | 1/10 | 3/10 | 0/4 |
| Blood creatine phosphokinase increasedInvestigations | 1/10 | 3/10 | 1/4 |
| Neutrophil count increasedInvestigations | 1/10 | 3/10 | 0/4 |
| Noninfective gingivitisGastrointestinal disorders | 0/10 | 0/10 | 1/4 |
| Blood triglycerides increasedInvestigations | 2/10 | 0/10 | 1/4 |
| Urinary occult blood positiveInvestigations | 0/10 | 0/10 | 1/4 |
| Weight increasedInvestigations | 0/10 | 1/10 | 1/4 |
| PresyncopeNervous system disorders | 0/10 | 0/10 | 1/4 |
All enrolled participants who received at least one dose of study drug.
| Age, Continuous(years) | 250 mg Lebrikizumab | 500 mg Lebrikizumab | Placebo | Total |
|---|---|---|---|---|
| Mean | 33.1 ± 8.08 | 29.1 ± 5.95 | 29.0 ± 6.22 | 30.8 ± 6.97 |
| Sex: Female, Male(Participants) | 250 mg Lebrikizumab | 500 mg Lebrikizumab | Placebo | Total |
|---|---|---|---|---|
| Female | 2 | 3 | 2 | 7 |
| Male | 8 | 7 | 2 | 17 |
| Ethnicity (NIH/OMB)(Participants) | 250 mg Lebrikizumab | 500 mg Lebrikizumab | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 10 | 10 | 4 | 24 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | 250 mg Lebrikizumab | 500 mg Lebrikizumab | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 10 | 10 | 4 | 24 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | 250 mg Lebrikizumab | 500 mg Lebrikizumab | Placebo | Total |
|---|---|---|---|---|
| China | 10 | 10 | 4 | 24 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2024 to primary completion in Sep 2024, 5 months.
Results were first posted in Sep 2025, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lebrikizumab